Product Pathways - Transcription Factors
SignalSilence® LRF/Pokemon siRNA I #13350
|13350S||300 µl (3 nmol)||---||In Stock||---|
|13350||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Western blot analysis of extracts from HeLa cells transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-) or SignalSilence® LRF/Pokemon siRNA I (+) using LRF/Pokemon Antibody #13097 (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower). The LRF/Pokemon Antibody confirms silencing of LRF/Pokemon expression, while the β-Actin (D6A8) Rabbit mAb is used as a loading control.
SignalSilence® LRF/Pokemon siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit LRF (pokemon) expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions For Use
CST recommends transfection with 100 nM SignalSilence® LRF/Pokemon siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
Zinc finger and BTB domain-containing protein 7A (LRF, Pokemon, FBI1) is a transcriptional repressor encoded by the ZBTB7A gene that belongs to the POK (POZ and Kruppel)/ZBTB (zinc finger and BTB) family (1). LRF is broadly expressed with elevated expression in a variety of cancers relative to normal tissues, including non-small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, and hepatocellular carcinoma (1-8). Research studies suggest that LRF acts as an oncogene through various mechanisms including repression of the tumor suppressors ARF and Rb, and repression of the cell cycle arrest factor p21Cip1 (9-11). The LRF transcription factor plays key roles during several stages of hematopoiesis including promoting lymphoid progenitor cells to commit to B cell differentiation by repressing T cell-promoting Notch signals, and promoting cell survival during terminal erythroid differentiation through suppression of the proapoptotic factor Bim (12,13).
- Lee, S.U. and Maeda, T. (2012) Immunol Rev 247, 107-19.
- Apostolopoulou, K. et al. (2007) J Pathol 213, 294-302.
- Zhao, Z.H. et al. (2008) Lung Cancer 62, 113-9.
- Qu, H. et al. (2010) Cancer Invest 28, 672-8.
- Aggarwal, A. et al. (2010) Exp Mol Pathol 89, 140-8.
- Jiang, L. et al. (2010) Mol Cancer 9, 318.
- Aggarwal, H. et al. (2011) Exp Mol Pathol 90, 226-30.
- Fang, F. et al. (2012) Cancer 118, 134-46.
- Maeda, T. et al. (2005) Nature 433, 278-85.
- Jeon, B.N. et al. (2008) J Biol Chem 283, 33199-210.
- Choi, W.I. et al. (2009) J Biol Chem 284, 12633-44.
- Maeda, T. et al. (2007) Science 316, 860-6.
- Maeda, T. et al. (2009) Dev Cell 17, 527-40.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
CST™ is a trademark of Cell Signaling Technology, Inc.
SignalSilence® is a trademark of Cell Signaling Technology, Inc.